TY - JOUR
T1 - Cancers of the corpus uteri treated in South Australian public hospitals
T2 - Trends in clinical management and survival across three decades
AU - Roder, David
AU - Selva-Nayagam, Sudarsha
AU - Paramasivam, Sellvakumaran
AU - Keefe, Dorothy
AU - Olver, Ian
AU - Miller, Caroline
AU - Buckley, Elizabeth
AU - Powell, Kate
AU - Fusco, Kellie
AU - Buranyi-Trevarton, Dianne
AU - Oehler, Martin
N1 - Funding Information:
The authors received funding support from Cancer Council's Beat Cancer Project on behalf of its donors and the State Government through the Department of Health. Funding bodies had no direct role in the collection, analysis, interpretation or writing of the manuscript.
Funding Information:
The authors received funding support from Cancer Council's Beat Cancer Project on behalf of its donors and the State Government through the Department of Health. Funding bodies had no direct role in the collection, analysis, interpretation or writing of the manuscript.
Publisher Copyright:
© 2020 John Wiley & Sons Ltd
PY - 2020/7/8
Y1 - 2020/7/8
N2 - Objective: To investigate treatment and survival over three decades. Methods: Clinical registry data from three major public hospitals analysed using Kaplan–Meier product-limit estimates and multivariate proportional hazard regression to determine disease-specific survival. Results: Five-year survival increased from 75% to 84%. The adjusted hazard ratio (HR, 95% CI) was 0.56 (0.41, 0.77) for 2010–2016 compared with 1984–1989 and was higher for: ages 80+ years; more advanced stages; poorly differentiated tumours; and complex mixed epithelial and mesenchymal tumours and sarcomas. Treatment was by surgery (92%), radiotherapy (33%), chemotherapy (12%) and hormone therapy (10%). Adjusted analyses showed radiotherapy and hormone therapy were less common from 1990 and chemotherapy more common for 2010–2016. Treatment likelihood was lower for ages ≥80 years, mixed epithelial and mesenchymal tumours receiving surgery and chemotherapy, but higher for radiotherapy. Advanced cancers (FIGO stage IV) had less surgery but more non-surgical treatments. Marginal evidence presented of more hormone therapy for high socio-economic areas. Conclusions: Survival was equivalent to national figures for Australia and the United States, but potentially higher than for England and Wales. Cases aged 80+ years had less care and poorer survival. Findings illustrate the complementary roles of hospital and population-based registries in local service evaluation.
AB - Objective: To investigate treatment and survival over three decades. Methods: Clinical registry data from three major public hospitals analysed using Kaplan–Meier product-limit estimates and multivariate proportional hazard regression to determine disease-specific survival. Results: Five-year survival increased from 75% to 84%. The adjusted hazard ratio (HR, 95% CI) was 0.56 (0.41, 0.77) for 2010–2016 compared with 1984–1989 and was higher for: ages 80+ years; more advanced stages; poorly differentiated tumours; and complex mixed epithelial and mesenchymal tumours and sarcomas. Treatment was by surgery (92%), radiotherapy (33%), chemotherapy (12%) and hormone therapy (10%). Adjusted analyses showed radiotherapy and hormone therapy were less common from 1990 and chemotherapy more common for 2010–2016. Treatment likelihood was lower for ages ≥80 years, mixed epithelial and mesenchymal tumours receiving surgery and chemotherapy, but higher for radiotherapy. Advanced cancers (FIGO stage IV) had less surgery but more non-surgical treatments. Marginal evidence presented of more hormone therapy for high socio-economic areas. Conclusions: Survival was equivalent to national figures for Australia and the United States, but potentially higher than for England and Wales. Cases aged 80+ years had less care and poorer survival. Findings illustrate the complementary roles of hospital and population-based registries in local service evaluation.
KW - cancer
KW - chemotherapy
KW - management
KW - radiotherapy
KW - staging
KW - surgery
UR - http://www.scopus.com/inward/record.url?scp=85087635744&partnerID=8YFLogxK
U2 - 10.1111/ecc.13281
DO - 10.1111/ecc.13281
M3 - Article
C2 - 32639088
AN - SCOPUS:85087635744
SN - 0961-5423
VL - 29
JO - European Journal of Cancer Care
JF - European Journal of Cancer Care
IS - 5
M1 - e13281
ER -